Dare Bioscience (DARE) Depreciation & Amortization (CF) (2013 - 2025)
Dare Bioscience's (DARE) quarterly Depreciation & Amortization (CF) came in at $534395.0 in Q4 2025, up 8291.88% YoY from $6368.0 in Q4 2024, and up 10.89% on a QoQ basis from $481906.0 in Q3 2025.
Dare Bioscience (DARE) Depreciation & Amortization (CF) (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $534395.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 8291.88% year-over-year to $534395.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 3761.75% YoY) and the FY2025 annual result came in at $1.6 million, up 3761.75% from the prior year.
- Depreciation & Amortization (CF) rose to $534395.0 in Q4 2025, from $481906.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $534395.0 in Q4 2025 to a low of $3034.0 in Q3 2022.
- A 5-year average of $88289.4 and a median of $9561.5 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 52.17% — and 2025, when it surged 8291.88%.
- Tracing DARE's Depreciation & Amortization (CF) over 5 years: stood at $7047.0 in 2021, then surged by 50.73% to $10622.0 in 2022, then fell by 6.04% to $9980.0 in 2023, then slumped by 36.19% to $6368.0 in 2024, then surged by 8291.88% to $534395.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $534395.0 (Q4 2025), $481906.0 (Q3 2025), and $460075.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 534,395.00 |
| Dec 31, 2025 | 534,395.00 |
| Sep 30, 2025 | 481,906.00 |
| Sep 30, 2025 | 481,906.00 |
| Jun 30, 2025 | 460,075.00 |
| Jun 30, 2025 | 460,075.00 |
| Mar 31, 2025 | 158,110.00 |
| Mar 31, 2025 | 158,110.00 |
| Dec 31, 2024 | 6,368.00 |
| Dec 31, 2024 | 6,368.00 |
| Sep 30, 2024 | 9,742.00 |
| Sep 30, 2024 | 9,742.00 |
| Jun 30, 2024 | 15,437.00 |
| Jun 30, 2024 | 15,437.00 |
| Mar 31, 2024 | 10,778.00 |
| Mar 31, 2024 | 10,778.00 |
| Dec 31, 2023 | 9,980.00 |
| Dec 31, 2023 | 9,980.00 |
| Sep 30, 2023 | 9,260.00 |
| Sep 30, 2023 | 9,260.00 |